Oxaver (Oxandrolone)

$61.18

Manufacturer : Vermodje
Model: 917
Availability:
Box: 10mg (50 tablets)
Ingredient: Oxandrolone (Anavar)

Category:

Description

General information about Oxaver in Belgium

OXAVER (Oxandrolone) is considered one of the mildest steroids available. It is mildly anabolic and mildly androgenic. Even though it is an oral C-17, it still has a minimal effect on liver values ​​even at higher doses. OXAVER (Oxandrolone) is also not known by bodybuilders as the steroid for big mass gains. On the contrary, the mass that is gained by OXAVER (oxandrolone) will be quality gains, and gains that are likely to be retained after the steroid is no longer used. Users of OXAVER (Oxandrolone) often notice a very good increase in strength.

Due to its extremely mild nature, OXAVER (Oxandrolone) is also one of the most popular steroids among female bodybuilders. OXAVER (Oxandrolone) has also been shown in studies to actually decrease body fat during use, making it an excellent choice for bodybuilders who are in the cutting phase of their training.

OXAVER (Oxandrolone) in Belgium is also very mild when it comes to shutting down the body's ability to produce testosterone, making it an excellent choice for anyone looking to 'bridge' between cycles while allowing the body to recover. Those looking to stack OXAVER (Oxandrolone) with something can choose a low dose of a testosterone to do with it.

Dosage in Belgium

Obviously, OXAVER (Oxandrolone) is a great all around steroid. Male bodybuilders usually use oxandrolone in doses of 50-100mg per day for 6-12wks. OXAVER (Oxandrolone) has a relatively short half-life of approximately 8 hours.Thus, one may choose to split the doses throughout the day in order to keep blood levels as stable as possible. Women bodybuilders generally find a dosage of 2.5-10mgs to be effective in promoting muscle gains and strength without the great risk of side effects.

Reviews

There are no reviews yet.

Be the first to review “Oxaver (Oxandrolone)”

Your email address will not be published. Required fields are marked *